[go: up one dir, main page]

MX2017013137A - Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. - Google Patents

Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.

Info

Publication number
MX2017013137A
MX2017013137A MX2017013137A MX2017013137A MX2017013137A MX 2017013137 A MX2017013137 A MX 2017013137A MX 2017013137 A MX2017013137 A MX 2017013137A MX 2017013137 A MX2017013137 A MX 2017013137A MX 2017013137 A MX2017013137 A MX 2017013137A
Authority
MX
Mexico
Prior art keywords
phoshoinositide
kinases inhibitors
chromene derivatives
kinases
chromene
Prior art date
Application number
MX2017013137A
Other languages
English (en)
Other versions
MX376090B (es
Inventor
Biagetti Matteo
Maria Capelli Anna
Accetta Alessandro
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2017013137A publication Critical patent/MX2017013137A/es
Publication of MX376090B publication Critical patent/MX376090B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a los compuestos que inhiben las fosfoinosítido-3-cinasas (PI3K), a las composiciones farmacéuticas que los comprenden y su uso terapéutico en el tratamiento de los trastornos asociados a las enzimas PI3K.
MX2017013137A 2015-04-16 2016-04-14 Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. MX376090B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15163902 2015-04-16
PCT/EP2016/058261 WO2016166239A1 (en) 2015-04-16 2016-04-14 Chromene derivatives as phoshoinositide 3-kinases inhibitors

Publications (2)

Publication Number Publication Date
MX2017013137A true MX2017013137A (es) 2018-02-21
MX376090B MX376090B (es) 2025-03-07

Family

ID=52991512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013137A MX376090B (es) 2015-04-16 2016-04-14 Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.

Country Status (12)

Country Link
US (1) US9968604B2 (es)
EP (1) EP3283481B1 (es)
KR (1) KR20170137127A (es)
CN (1) CN107454902B (es)
AR (1) AR104262A1 (es)
BR (1) BR112017022158B1 (es)
CA (1) CA2982631A1 (es)
HK (1) HK1246779A1 (es)
MX (1) MX376090B (es)
RU (1) RU2722383C2 (es)
TR (1) TR201907614T4 (es)
WO (1) WO2016166239A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020007593A2 (pt) * 2017-10-18 2020-09-24 Incyte Corporation derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama
CA3091202A1 (en) * 2018-02-27 2019-09-06 Artax Biopharma Inc. Chromene derivatives as inhibitors of tcr-nck interaction
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
WO2020200918A1 (en) * 2019-04-04 2020-10-08 Chiesi Farmaceutici S.P.A. Isochromene derivatives as phosphoinositide 3-kinases inhibitors
CN111346095B (zh) * 2020-03-14 2021-06-08 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 用于治疗神经外科术后头痛的药物制剂
CN114891005B (zh) * 2022-03-30 2024-01-19 武汉九州钰民医药科技有限公司 一种乌帕利斯对甲苯磺酸盐的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772761B1 (fr) 1997-12-23 2000-05-26 Lipha Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
FR2797874B1 (fr) 1999-08-27 2002-03-29 Adir Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL162810A0 (en) 2002-01-11 2005-11-20 Takeda Pharmaceutical coumarin derivatives, process for their productionand use thereof
DE102007018072A1 (de) 2007-04-17 2008-10-30 Volkswagen Ag Anzeigeeinrichtung für ein Fahrzeug zum Anzeigen von den Betrieb des Fahrzeugs betreffende Informationen und Verfahren zum Anzeigen dieser Informationen
HRP20171537T1 (hr) * 2009-11-05 2017-12-15 Rhizen Pharmaceuticals S.A. Novi modulatori benzopiran kinaze
ES2379242B1 (es) 2010-09-28 2013-03-04 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromeno.
CN102746281B (zh) * 2011-04-22 2015-01-14 四川大学 4-1,2,3-三氮唑-香豆素衍生物及其制备方法和用途
KR101992311B1 (ko) * 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
EP2968345B1 (en) 2013-03-13 2017-12-13 The Regents of The University of Michigan Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases
AR098776A1 (es) 2013-12-18 2016-06-15 Chiesi Farm Spa Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas

Also Published As

Publication number Publication date
EP3283481A1 (en) 2018-02-21
RU2722383C2 (ru) 2020-05-29
BR112017022158B1 (pt) 2024-01-09
CN107454902A (zh) 2017-12-08
MX376090B (es) 2025-03-07
CN107454902B (zh) 2020-09-15
RU2017134899A (ru) 2019-05-16
US20160303123A1 (en) 2016-10-20
TR201907614T4 (tr) 2019-06-21
WO2016166239A1 (en) 2016-10-20
CA2982631A1 (en) 2016-10-20
KR20170137127A (ko) 2017-12-12
HK1246779A1 (zh) 2018-09-14
EP3283481B1 (en) 2019-03-13
US9968604B2 (en) 2018-05-15
RU2017134899A3 (es) 2019-06-17
BR112017022158A2 (pt) 2018-07-03
AR104262A1 (es) 2017-07-05

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2017013556A (es) Compuestos novedosos.
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CL2015002473A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la phd.
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY35747A (es) Derivados sustituidos de fenilalanina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CR20160133A (es) Derivados de fenilalanina sustituidos
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina

Legal Events

Date Code Title Description
FG Grant or registration